capAI PLC Executes Licence and Option Agreement for AI-Powered Game42 Platform

Option to acquire the IP: price, structure and control

capAI holds a discretionary option to acquire 100% of the Game42 intellectual property at any time during the Licence Period for £2.0 million. Importantly, capAI cannot be forced to exercise. If it does exercise, consideration is settled by:

• New Ordinary Shares valued using the 20-trading day volume-weighted average price prior to exercise; or
• A mix of shares and non-transferable unsecured convertible loan notes (UCLNs) if regulatory constraints apply. The UCLNs carry a 10% non-compounding annual interest rate.

Any shares issued (including on UCLN conversion) are expected to be admitted to the FCA’s Official List (equity shares transition category) and to trading on the LSE Main Market.

On completion of the IP transfer, R42 retains 20% of net proceeds from any monetisation, sale or liquidity event of all or substantially all of the Game42 IP. That preserves alignment but does skim upside on a future disposal. If capAI does not exercise the option within the Licence Period, all rights – including any improvements or derivative works created by capAI – revert to R42.

Related party and governance – what’s been done

The LOA is a material related party transaction under DTR 7.3 because R42 is connected with Professor Ronjon Nag (an Executive Director). He recused himself from deliberations. The independent directors – Richard Edwards, Sarah Davy and Marcus Yeoman – considered the transaction fair and reasonable for the Company and non-related shareholders.

Exercising the option would likely constitute a substantial property transaction under section 190 of the Companies Act 2006, given the £2.0 million consideration. The Board may therefore seek shareholder approval at a forthcoming general meeting to pre-clear that step, signalling a belt-and-braces approach to governance.

Key terms at a glance

Counterparty	R42 Group LLC
Asset	Game42 generative AI book-to-game platform
Scope	Exclusive worldwide licence to use, develop, commercialise and sub-license
Control	Full operational and strategic control during the Licence Period
Upfront consideration	None
Licence Period	12 months from Completion Notice
MVP target (non-binding)	31 December 2025
Long-stop/termination	Either party can terminate if no Completion Notice by 30 June 2026
Option to acquire IP	Discretionary, exercisable during Licence Period
Option price	£2,000,000
Consideration form	New Ordinary Shares (20-day VWAP) and/or UCLNs at 10% non-compounding
Exit participation	R42 entitled to 20% of net proceeds on any monetisation/sale of substantially all IP post-transfer
Reversion	All rights (including improvements) revert to R42 if option not exercised within Licence Period
Governance	Related party transaction approved by independent directors; potential s190 shareholder vote

My take: the positives

• No upfront cash – capAI secures exclusivity and control without writing a cheque today. That is capital-light optionality.
• Clear sequencing – Author42 live, Creator42 next, Game42 after. Investors get a roadmap rather than a scattergun.
• Commercial leverage – the ability to sub-license and cross-sell to Author42/Creator42 users could widen the funnel.
• Option, not obligation – capAI can test commercial traction before stumping up £2.0 million for full IP ownership.
• Governance signals – related party handled via independent approval, and pre-emptive thinking on a potential s190 vote.

And the watch-outs

• Timeline risk – the MVP date is a target, not a commitment. The long-stop is 30 June 2026, after which the deal can unwind.
• Reversion sting – if capAI doesn’t exercise the option, even its own improvements revert to R42. That puts pressure on delivery and decision-making during the Licence Period.
• Future cost of capital – if shares are used for the £2.0 million, there’s dilution; if UCLNs are used, the 10% rate is punchy.
• Residual economics – even after acquiring the IP, capAI would share 20% of net proceeds on a future IP sale or monetisation event with R42, trimming exit upside.

Why this matters for valuation

For now, this is about strategic positioning and optionality rather than immediate revenue. If Game42 hits MVP on time, capAI gains a 12-month window of exclusive control to prove product-market fit, sign partners and start monetising without upfront cash outlay. If momentum builds, the Board can justify exercising the option and bringing the IP fully in-house.

If timelines slip or traction disappoints, capAI can step back with limited sunk cost. That asymmetry – upside exposure with downside protection – is the crux of today’s announcement.

What to watch next

• Definition of MVP criteria and the formal Completion Notice process – this is the gate to all licence rights.
• Evidence of early partners or pilot projects that validate demand across authors, studios and IP holders.
• Commercial terms for sub-licensing and any bundling with Author42/Creator42 clients.
• Any move to seek shareholder approval under s190 ahead of potential option exercise.
• Funding mix preferences if the option is exercised – shares vs UCLNs, and associated dilution implications.

Bottom line

This is a neat, low-cost way for capAI to extend into gaming with a clear decision point later. The structure keeps cash in the bank today, gives strategic control when the product is ready, and preserves the right – but not the obligation – to own the IP outright. Delivery against the MVP timeline and early commercial wins will decide whether this option becomes a must-exercise or a pass.